CEL-SCI Extends Its Phase III Head And Neck Cancer Trial To Canada

(RTTNews) - CEL-SCI Corp. (CVM) Tuesday said it has expanded its Phase III Head and Neck Cancer Trial of its investigational cancer immunotherapy treatment Multikine into Centre Hospitalier Universitaire de Quebec in Canada.

The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The trial aims to achieve a statistically significant improvement in overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care vs. subjects who are treated with SOC only.

"We are adding many additional centers in Canada and the U.S. for the world's largest Phase III trial in head and neck cancer. This will hopefully keep us on schedule to complete global enrollment with approximately 880 patients by the end of 2015," said the company's CEO Geert Kersten in a statement.